Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Knott David M Jr

Knott David M Jr lowered its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 36.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 120,000 shares of the biopharmaceutical company’s stock after selling 69,000 shares during the period. Catalyst Pharmaceuticals makes up 1.8% of Knott David M Jr’s holdings, making the stock its 18th largest position. Knott David M Jr owned approximately 0.10% of Catalyst Pharmaceuticals worth $2,971,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Advisory Services Network LLC acquired a new position in shares of Catalyst Pharmaceuticals during the third quarter valued at $39,000. Quarry LP acquired a new stake in Catalyst Pharmaceuticals in the third quarter worth about $40,000. Clearstead Advisors LLC lifted its holdings in Catalyst Pharmaceuticals by 192.9% in the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 1,167 shares during the period. Smartleaf Asset Management LLC grew its position in Catalyst Pharmaceuticals by 55.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 630 shares in the last quarter. Finally, Larson Financial Group LLC grew its position in Catalyst Pharmaceuticals by 552.7% in the 4th quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 1,564 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Analyst Upgrades and Downgrades

CPRX has been the topic of several research analyst reports. Citigroup cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $35.00 to $31.50 in a research note on Friday, May 8th. HC Wainwright lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $35.00 to $31.50 in a research note on Thursday, May 28th. Zacks Research cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Friday, March 27th. Finally, Weiss Ratings raised Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock opened at $31.49 on Friday. The company’s 50-day moving average price is $31.38 and its two-hundred day moving average price is $27.27. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.05 and a 52 week high of $32.56. The stock has a market cap of $3.86 billion, a PE ratio of 18.10, a price-to-earnings-growth ratio of 0.96 and a beta of 0.74.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).